Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain

European Journal of Pain

Volumn 14, Issue 4, 2010, Pages 387-394

  Huge, Volker ^a   Lauchart, Meike ^a   Magerl, Walter ^b   Schelling, Gustav ^a   Beyer, Antje ^a   Thieme, Detlef ^c   Azad, Shahnaz C ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Institute of Doping Analysis and Sports Biochemistry   (Germany)

Author keywords

(S) norketamine; Breakthrough pain; Intranasal (S) ketamine; Neuropathic pain; Quantitative sensory testing

Indexed keywords

DRUG METABOLITE; KETAMINE; KETANEST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NORKETAMINE; UNCLASSIFIED DRUG;

ADULT; ANALGESIA; ARTICLE; BLURRED VISION; CLINICAL ARTICLE; CONFUSION; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LOW DRUG DOSE; MALE; MASS SPECTROMETRY; NAUSEA; NEUROPATHIC PAIN; NOISE INJURY; PAIN ASSESSMENT; PAIN THRESHOLD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEDATION; SENSORY SYSTEM EXAMINATION; SIDE EFFECT; SKIN; VERTIGO; VOMITING;

ADMINISTRATION, INTRANASAL; ADULT; AGED; ALGORITHMS; ANESTHETICS, DISSOCIATIVE; CARDIOVASCULAR SYSTEM; FEMALE; HEMODYNAMICS; HUMANS; KETAMINE; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; STEREOISOMERISM;

EID: 77949912800     PISSN: 10903801     EISSN: 15322149     Source Type: Journal    
DOI: 10.1016/j.ejpain.2009.08.002     Document Type: Article

References (37)

1. Arendt-Nielsen L., Petersen-Felix S., Fischer M., Bak P., Bjerring P., and Zbinden A.M. The effect of N-methyl-d-aspartate antagonist (ketamine) on single and repeated nociceptive stimuli: a placebo-controlled experimental human study. Anesth Analg 81 (1995) 63-68
2. Baad-Hansen L., Juhl G.I., Jensen T.S., Brandsborg B., and Svensson P. Differential effect of intravenous S-ketamine and fentanyl on atypical odontalgia and capsaicin-evoked pain. Pain 129 (2007) 46-54
3. Bell R.F., and Kalso E. Is intranasal ketamine an appropriate treatment for chronic non-cancer breakthrough pain?. Pain 108 (2004) 1-2
4. Bell R.F., Eccleston C., and Kalso E. Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review. J Pain Symptom Manage 26 (2003) 867-875
5. Bowdle T.A., Radant A.D., Cowley D.S., Kharasch E.D., Strassman R.J., and Roy-Byrne P.P. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 88 (1998) 82-88
6. Carr D.B., Goudas L.C., Denman W.T., Brookoff D., Staats P.S., Brennen L., et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. Pain 108 (2004) 17-27
7. Chizh B.A., and Headley P.M. NMDA antagonists and neuropathic pain - multiple drug targets and multiple uses. Curr Pharm Des 11 (2005) 2977-2994
8. De Kock M.F., and Lavand'homme P.M. The clinical role of NMDA receptor antagonists for the treatment of postoperative pain. Best Pract Res Clin Anaesthesiol 21 (2007) 85-98
9. Dworkin R.H., O'Connor A.B., Backonja M., Farrar J.T., Finnerup N.B., Jensen T.S., et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132 (2007) 237-251
10. Ebert B., Mikkelsen S., Thorkildsen C., and Borgbjerg F.M. Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol 333 (1997) 99-104
11. Eide P.K., Stubhaug A., Øye I., and Breivik H. Continuous subcutaneous administration of the N-methyl-d-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia. Pain 61 (1995) 221-228
12. Elia N., and Tramèr M.R. Ketamine and postoperative pain - a quantitative systematic review of randomised trials. Pain 113 (2005) 61-70
13. Fitzgibbon D., Morgan D., Dockter D., Barry C., and Kharasch E.D. Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients. Pain 106 (2003) 309-315
14. Geber C., Magerl W., Fondel R., Fechir M., Rolke R., Vogt T., et al. Numbness in clinical and experimental pain - a cross-sectional study exploring the mechanisms of reduced tactile function. Pain 139 (2008) 73-81
15. Geisslinger G., Hering W., Thomann P., Knoll R., Kamp H.D., and Brune K. Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method. Brit J Anaesth 70 (1993) 666-671
16. Holtman J., Crooks P.A., Johnson-Hardy J.K., Hojomat M., Kleven M., and Wala E.P. Effects of norketamine enantiomers in rodent models of persistent pain. Pharmacol Biochem Behav 90 (2008) 676-685
17. Huge V., Lauchart M., Förderreuther S., Kaufhold W., Valet M., Azad S.C., et al. Interaction of hyperalgesia and sensory loss in Complex Regional Pain Syndrome Type I (CRPS I). PLoS ONE 3 (2008) e2742
18. Kern D., Pelle-Lancien E., Luce V., and Bouhassira D. Pharmacological dissection of the paradoxical pain induced by a thermal grill. Pain 135 (2008) 291-299
19. Klein T., Magerl W., Rolke R., and Treede R.D. Human surrogate models of neuropathic pain. Pain 115 (2005) 227-233
20. Klein T., Magerl W., Nickel U., Hopf H.C., Sandkühler J., and Treede R.D. Effects of the NMDA-receptor antagonist ketamine on perceptual correlates of long-term potentiation within the nociceptive system. Neuropharmacology 52 (2007) 655-661
21. Klein T., Magerl W., Hanschmann A., Althaus M., and Treede R.D. Antihyperalgesic and analgesic properties of the N-methyl-d-aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic hyperalgesia. Eur J Pain 12 (2008) 17-29
22. Koppert W., Dern S.K., Sittl R., Albrecht S., Schüttler J., and Schmelz M. A new model of electrically evoked pain and hyperalgesia in human skin: the effects of intravenous alfentanil, S(+)-ketamine, and lidocaine. Anesthesiology 95 (2001) 395-402
23. Lavand'homme P., De Kock M., and Waterloos H. Intraoperative epidural analgesia combined with ketamine provides effective preventive analgesia in patients undergoing major digestive surgery. Anesthesiology 103 (2005) 813-820
24. Liu X.J., Gingrich J.R., Vargas-Caballero M., Dong Y.N., Sengar A., Beggs S., et al. Treatment of inflammatory and neuropathic pain by uncoupling Src from the NMDA receptor complex. Nat Med 14 (2008) 1325-1332
25. Malinovsky J.M., Servin F., Cozian A., Lepage J.Y., and Pinaud M. Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. Brit J Anaesth 77 (1996) 203-207
26. Muir K.W. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol 6 (2006) 53-60
27. Parsons C.G. NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol 429 (2001) 71-78
28. Petrenko A.B., Yamakura T., Askalany A.R., Kohno T., Sakimura K., and Baba H. Effects of ketamine on acute somatic nociception in wild-type and N-methyl-d-aspartate (NMDA) receptor ε1 subunit knockout mice. Neuropharmacology 50 (2006) 741-747
29. Pfenninger E.G., Durieux M.E., and Himmelseher S. Cognitive impairment after small-dose ketamine isomers in comparison to equianalgesic racemic ketamine in human volunteers. Anesthesiology 96 (2002) 357-366
30. Rabben T., Skjelbred P., and Øye I. Prolonged analgesic effect of ketamine, an N-methyl-d-aspartate receptor inhibitor, in patients with chronic pain. J Pharmacol Exp Ther 289 (1999) 1060-1066
31. Rolke R., Baron R., Maier C., Tölle T.R., Treede R.D., Beyer A., et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain 123 (2006) 231-243
32. Rolke R., Magerl W., Campbell K.A., Schalber C., Caspari S., Birklein F., et al. Quantitative sensory testing: a comprehensive protocol for clinical trials. Eur J Pain 10 (2006) 77-88
33. Verdugo R., and Ochoa J.L. Quantitative somatosensory thermotest. A key method for functional evaluation of small calibre afferent channels. Brain 115 (1992) 893-913
34. Woolf C.J. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 140 (2004) 441-451
35. Woolf C.J., and Max M.B. Mechanism-based pain diagnosis: issues for analgesic drug development. Anesthesiology 95 (2001) 241-249
36. Woolf C.J., and Salter M.W. Neuronal plasticity: increasing the gain in pain. Science 288 (2000) 1765-1769
37. Yanagihara Y., Ohtani M., Kariya S., Uchino K., Hiraishi T., Ashizawa N., et al. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos 24 (2003) 37-43